アルコール依存症の治療のための経口トピラマート:ランダム化制御試験

Bankole A Johnson¹, Nassima Ait-Daoud, Charles L Bowden

¹Department of Psychiatry, University of Texas Health Science Center at San Antonio, TX 78229-3900, USA. bjohnson@uthscsa.edu <bjohnson@uthscsa.edu>

Lancet (London, England)

|May 28, 2003

まとめ

トピラマートは,アルコール依存症の個体においてプラセボと比較して,アルコール消費と嗜好を著しく減少させた. この研究では,トピラマートがトピラマートであることを示しています.

科学分野:

神経科学は神経科学である.
薬理学薬理学とは
クリニック・トライアル臨床試験

背景:

トピラマートは,硫酸塩フルクトピラノースの誘導体であり,アルコールの報酬効果を低下させる可能性があります.
ドーパミンの放出を阻害し,GABAとグルタミン酸の活性を調節することによって潜在的に作用します.

研究の目的:

アルコール依存症の治療におけるトピラマートとプラセボの有効性を評価する.
トピラマートの飲酒行動と渇望への影響を評価するために.

主な方法:

アルコール依存症の150人の参加者を対象とした12週間の,ダブルブラインド,ランダム化制御試験.
参加者は,標準化された薬物準拠管理に加えて,経口トピラマート (25-300 mg/日) またはプラセボを投与されました.
主なアウトカムには,自己報告された飲酒パターンとプラズマのガンマグルタミルトランスファーゼレベルが含まれ,渇望は二次的アウトカムでした.

主要な成果:

トピラマート群は,プラセボと比較して,1日および1日の飲酒量が有意に少なかった.
トピラマート投与の参加者は,禁酒日数が多く,重度の飲酒日数が少なくなった.
トピラマート群では,プラズマのガンマグルタミルトランスファーゼと自己報告された食欲の有意な減少が観察されました.

結論:

トピラマートは,1日最大300mgの投与で,アルコール依存症の治療にプラセボよりも効果的です.
トピラマートは,アルコール依存症の標準化された薬物準拠管理に有効な補助剤として機能します.

さらに関連する動画

05:40

The Motivation for Alcohol Reward: Predictors of Progressive-Ratio Intravenous Alcohol Self-Administration in Humans

Published on: April 28, 2022

05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

関連する概念動画

01:17

Drug Dependence

Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...

01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...

01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...

01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...

01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

関連する実験動画